Open AccessRedistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
Author(s) -
Kevin C. Conlon,
Enrico Lugli,
Hugh C. Welles,
Steven A. Rosenberg,
Antonio Tito Fojo,
John C. Morris,
Thomas A. Fleisher,
Sigrid Dubois,
Liyanage P. Perera,
Donn M. Stewart,
Carolyn K. Goldman,
Bonita R. Bryant,
Jean M. Decker,
Jing Chen,
Tatyana Worthy,
William D. Figg,
Cody J. Peer,
Michael C. Sneller,
H. Clifford Lane,
Jason L. Yovandich,
Stephen P. Creekmore,
Mario Roederer,
Thomas A. Waldmann
Publication year - 2014
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2014.57.3329
Subject(s) - medicine , cd8 , cytotoxic t cell , immunotherapy , aldesleukin , cytokine , interleukin 2 , immunology , pharmacology , cancer , immune system , biology , in vitro , biochemistry
Interleukin-15 (IL-15) has significant potential in cancer immunotherapy as an activator of antitumor CD8 T and natural killer (NK) cells. The primary objectives of this trial were to determine safety, adverse event profile, dose-limiting toxicity, and maximum-tolerated dose of recombinant human IL-15 (rhIL-15) administered as a daily intravenous bolus infusion for 12 consecutive days in patients with metastatic malignancy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom